# 6621
The only thing truly constant with influenza viruses is that they are continually changing. As flu viruses leave behind varying levels of immunity in those they infect - were they not to change over time - they would soon die out due to a lack of susceptible hosts.
Influenza viruses evolve via two well established routes; Antigenic drift and Antigenic Shift (reassortment).
Antigenic drift causes small, incremental changes in the virus over time. Drift is the standard evolutionary process of influenza viruses, and often come about due to replication errors that are common with single-strand RNA viruses.
Shift occurs when one virus swap out chunks of their genetic code with gene segments from another virus. This is known as reassortment. While far less common than drift, shift can produce abrupt, dramatic, and sometimes pandemic inducing changes to the virus.
For shift to happen, a host (human, swine, bird) must be infected by two influenza different viruses at the same time.
Reassortment of two Flu viruses
While successful reassortment is relatively rare, as any virologist will tell you . . . Shift happens.
While we talk about four main strains of influenza that currently circulate in humans (A/H1N1(pdm), A/H3N2, B Victoria, B Yamagata), in reality – within each strain - you will find a good deal of diversity.
New `prototypes’ from these strains are constantly being generated and are then immediately`field tested’ for biological fitness and transmissibility.
Most fail miserably.
But occasionally, a new, biologically fit virus will emerge that can outcompete its parental strains, and it begins to spread rapidly.
Since flu vaccine formulations must be decided upon six months before they can be deployed, public health agencies like the CDC, ECDC, Hong Kong’s CHP (and others) spend considerable resources on influenza surveillance, looking for signs of any up-and-coming viral strains.
Once each month the ECDC issues an influenza characterization report, showing what changes have been detected in the influenza viruses circulating in Europe.
Below you’ll find a link to their recent report, and a brief summary of the highlights.
Influenza virus characterisation - Summary Europe, September 2012
ABSTRACT
Since 01 January 2012, influenza A(H1N1)pdm09, influenza A(H3N2) and influenza B/Victoria and B/Yamagata lineage viruses have been detected in ECDC-affiliated countries.
- Type A viruses have predominated over type B.
- A(H3N2) viruses have predominated over A(H1N1)pdm09 viruses.
- A(H1N1)pdm09 viruses continue to show genetic drift from the vaccine virus, A/California/07/2009, but the vast majority remain antigenically similar to it.
- During the last nine months, all European A(H3N2) viruses sequenced fell within five genetic clusters. Test viruses isolated in mammalian cells show low titres with post-infection ferret antisera raised against egg-propagated viruses, including the new vaccine virus A/Victoria/361/2011. They react well with post-infection ferret antisera raised against A/Victoria/361/2011 and other current reference viruses propagated exclusively in tissue culture.
- Recent B/Victoria lineage viruses fell within the B/Brisbane/60/2008 genetic clade and were antigenically similar to reference cell-propagated viruses of the B/Brisbane/60/2008 genetic clade.
- Recent B/Yamagata-lineage viruses fell into two genetic clades, represented by the recommended vaccine component for the 2012/2013 influenza season, B/Wisconsin/1/2010 (clade 3), or B/Estonia/55669/2012 (clade 2); viruses in these clades are antigenically distinguishable.
- Antigenic analyses of A(H3N2)v viruses, the cause of zoonotic infections in the USA, indicate that these viruses are antigenically distinct from seasonal A(H3N2) viruses.
The best news in this report is that most of the newest iterations of the (now seasonal) 2009 pandemic H1N1 virus continue to be antigenically similar to the original virus, and this year’s vaccine should be reasonably effective against it.
As for the growing diversity and antigenic drift among the A/H3N2 viruses (now 5 distinct subtypes), we’ll have to wait to see how much of an impact they will have on the overall VE (Vaccine Effectiveness) of this year’s flu vaccine.
We are also seeing signs of divergence in the Yamagata lineage between this year’s vaccine component clade 3 virus (B/Wisconsin/1/2010) virus and a newer clade 2 virus (B/Estonia/55669/2012).
Despite the inevitable diversity being reported in flu viruses across Europe, the World Health Organization recently released their Southern Hemisphere 2013 Flu Vaccine Composition recommendations, which remain unchanged from this fall’s vaccine.
Which is a pretty good indication that their confidence in the makeup of this fall’s flu vaccine remains high.
Related Post:
- The Many Flavors Of ILI
- Canada Releases Tamiflu From National Emergency Stockpile
- CDC Statement On This Year’s Flu Activity
- ECDC Influenza Virus Characterization
- BMC: Exploring The `Age Shift’ Of Pandemic Mortality
- PLoS One: Influenza Viral Shedding & Asymptomatic Infections
- Influenza Virus Survival At Opposite Ends Of The Humidity Spectrum
- NIVW 2012
- Revisiting The Numbers Racket
- Of Pregnancy, Flu & Autism
- Study: Adverse Events Associated With Oseltamivir Outpatient Treatment
- MMWR: Evaluating RIDTs
- CIDRAP: The Need For `Game Changing’ Flu Vaccines
- Study: Influenza And Heart Attacks
- Dozens Of Ways To Spell `I-L-I’
- Companion Animals & Reverse Zoonosis
- A WHO Flu Review
- NPM12: The Rehydration Solution
- NIAID Video: How Influenza Pandemics Occur
- IDSA: Pandemic and Seasonal Influenza Preparedness
- CDC Updates Minnesota H1N2v Cases
- An Increasingly Complex Flu Field
- When Body Caught Flu Infected? flu incubation period
- HOW TO RECOGNIZE COMMON FLU FLU AND DANGEROUS to children
- Lancet: Low Flu Vaccine Effectiveness
- ECDC Influenza Virus Characterization
- ECDC: Updated Novel Coronavirus Risk Assessment
- ECDC Updates Their Coronavirus Risk Assessment
- ECDC Risk Assessment: Dengue In Madeira
- WHO Europe: Revising Pandemic Preparedness Plans
- ECDC: Multidrug Resistant Infections Increasing In Europe
- Global Flu Surveillance Updates
- Updated ECDC Risk Assessment On Coronavirus
- EID Journal: Challenges To Defining TDR-TB
- ECDC: Coronavirus `does not signal the start of a new SARS outbreak’
- ECDC Report: Narcolepsy In Association With Pandemic Flu Vaccination
- ECDC Risk Assessment On DR Congo Ebola Outbreak
- H3N2v: CDC Update & ECDC Risk Assessment
- ECDC: Climatic Suitability For Dengue Transmission in Europe
- Updating The Cambodian `Mystery’ Illness
- ECDC: Risk Assessment On Edinburgh Legionella Outbreak
- ECDC Response Plan To Multi-Drug Resistant Gonorrhea
- ECDC: Communicable Disease Threats -Week 23
- How The ECDC Will Spend Your Summer Vacation
- ECDC: Mapping Disease Vectors
- ECDC: Status & Importance Of Invasive Mosquito Breeds In Europe
- WHO-ECDC: Joint Report On Tuberculosis In Europe
- ECDC: Annual Risk Assessment On Seasonal Flu 2011-2012
- HPA: Flu Activity In The UK
- FluView, FluWatch, And WHO Flu Surveillance Reports
- Global Flu Surveillance Updates
- H3N2v Update: CDC Reports 52 New Cases, Limited H2H Transmission
- H3N2v: When Pigs Flu
- The 2012 Flu Season Down Under
- WER: Reviewing The 2011-2012 Northern Hemisphere Flu Season
- How The ECDC Will Spend Your Summer Vacation
- Hong Kong: Flu Activity Continues To Rise
- CDC: The Close Of A Mild Season
- Hong Kong Swine Flu Virus Surveillance
- WHO: 2012 World Health Statistics Report
- USGS: New Real-Time Earthquake Map
- Global H5N1 Blind Spots
- Nature: Views & Opinions On Tracking H5N1
- WHO-ECDC: Joint Report On Tuberculosis In Europe
- CDC: FluView Week 10
- Hong Kong Swine Influenza Surveillance
- A Flu Flew Review
- EuroFlu: H3N2 Dominates But Overall Activity Is Low
- Indonesia To Increase Surveillance For H5N1: MOH
- WHO Comment: Testing For Novel Flu Viruses
- CIDRAP: New Details In The trH3N2 Story
- Hong Kong: Swine Influenza Surveillance
Widget by [ Iptek-4u ]